{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:03:24Z","timestamp":1771927404183,"version":"3.50.1"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The advent of cancer immunotherapies, including immune checkpoint inhibitors (ICI), Chimeric antigen receptor (CAR-T) cell therapies, and bispecific antibodies and other immune-activating platforms such as therapeutic vaccines and oncolytic viruses (often used in combination regimens) has revolutionized oncology by improving patient outcomes across diverse malignancies. However, these therapies are increasingly linked to cardiovascular toxicities such as myocarditis, arrhythmias, and heart failure, posing significant clinical challenges. Here we review current evidence on the mechanisms, clinical manifestations, diagnostic approaches, and management strategies of immunotherapy-associated cardiotoxicities, emphasizing the role of cardio-oncology in integrating cardiovascular care with cancer treatment. We also discuss emerging immunotherapies and their potential cardiac effects. Understanding these complexities is critical to optimizing patient safety and treatment efficacy. Continued interdisciplinary research and standardized clinical protocols are essential to advance early detection, risk stratification, and tailored interventions, thereby preserving the therapeutic benefits of immunotherapy while mitigating cardiovascular risks.<\/jats:p>","DOI":"10.3389\/fphar.2026.1762239","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T05:41:17Z","timestamp":1769406077000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Guarding the heart in the era of immunotherapies: insights for cardio-oncology practice"],"prefix":"10.3389","volume":"17","author":[{"given":"Umamah","family":"Iram","sequence":"first","affiliation":[{"name":"Department of Physiology, The University of Tennessee Health Science Center","place":["Memphis, TN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djamel","family":"Lebeche","sequence":"additional","affiliation":[{"name":"Department of Physiology, The University of Tennessee Health Science Center","place":["Memphis, TN, United States"]},{"name":"Department of Medicine, The University of Tennessee Health Science Center","place":["Memphis, TN, United States"]},{"name":"Neuroscience Institute, College of Medicine, The University of Tennessee Health Science Center","place":["Memphis, TN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12967-025-06543-x","article-title":"Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed\/refractory multiple myeloma","volume":"23","author":"An","year":"2025","journal-title":"J. Transl. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B3","unstructured":"2024"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s11239-025-03146-7","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management","volume":"58","author":"Becker","year":"2025","journal-title":"J. Thromb. Thrombolysis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1090103","DOI":"10.3389\/fcvm.2023.1090103","article-title":"Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: a clinical appraisal","volume":"10","author":"Camilli","year":"2023","journal-title":"Front. Cardiovasc Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1601808","DOI":"10.3389\/fonc.2025.1601808","article-title":"Cardiovascular adverse effects of immunotherapy in cancer: insights and implications","volume":"15","author":"Du","year":"2025","journal-title":"Front. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"15330338221132927","DOI":"10.1177\/15330338221132927","article-title":"Adverse cardiac effects of CAR T-cell therapy: characteristics, surveillance, management, and future research directions","volume":"21","author":"Dalal","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"key":"B10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv."},{"key":"B12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00395-024-01046-0","article-title":"Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin","volume":"120","author":"Efentakis","year":"2025","journal-title":"Basic Res. Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","article-title":"Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives","volume":"74","author":"Ganatra","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-cell antineoplastic therapies: JACC: CardioOncology primer","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13256-023-04310-4","article-title":"Granulomatous myocarditis arising from intravesical Bacillus Calmette-Gu\u00e9rin therapy leading to death diagnosed by postmortem examination: a case report","volume":"18","author":"Geetha","year":"2024","journal-title":"J. Med. Case Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Goyco Vera","year":"2024","journal-title":"Hum. Vaccin Immunother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/jha2.906","article-title":"Fast but not so furious: a condensed step-up dosing schedule of teclistamab for relapsed\/refractory multiple myeloma","volume":"5","author":"Graf","year":"2024","journal-title":"EJHaem"},{"key":"B22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s44325-025-00057-7","article-title":"Cardiovascular complications of cellular immunotherapies and associated risk factors","volume":"2","author":"Grunblatt","year":"2025","journal-title":"Npj Cardiovasc Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/FJC.0000000000001456","article-title":"Treatment of immune checkpoint inhibitor-associated myocarditis","volume":"83","author":"Heemelaar","year":"2024","journal-title":"J. Cardiovasc Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/cancers17050827","article-title":"Characterizing cardiotoxicity of FDA-approved soft tissue Sarcoma targeted therapies and immune checkpoint inhibitors: a systematic review","volume":"17","author":"Houmsse","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2991\/chi.k.210718.001","article-title":"High sensitivity troponin T and NT-proBNP in patients receiving chimeric antigen receptor (CAR) T-cell therapy","volume":"3","author":"Hu","year":"2021","journal-title":"Clin. Hematol. Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1172\/JCI20149","article-title":"Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy","volume":"113","author":"Jahns","year":"2004","journal-title":"J. Clin. Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s43046-025-00262-6","article-title":"From lab to lifesaver: the rise of CAR T-cell therapy in oncology","volume":"37","author":"Jangavali","year":"2025","journal-title":"J. Egypt Natl. Canc Inst."},{"key":"B29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40959-023-00166-1","article-title":"Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance","volume":"9","author":"Jimenez","year":"2023","journal-title":"Cardiooncology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11912-024-01634-2","article-title":"Cardiotoxic effects following CAR-T cell therapy: a literature review","volume":"27","author":"Joseph","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e006072","DOI":"10.1136\/jitc-2022-006072","article-title":"Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer","volume":"11","author":"Khorana","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e2437222","DOI":"10.1001\/jamanetworkopen.2024.37222","article-title":"Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: a meta-analysis","volume":"7","author":"Koeckerling","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1347140","DOI":"10.3389\/fonc.2024.1347140","article-title":"Immunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies","volume":"14","author":"Kong","year":"","journal-title":"Front. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.20892\/j.issn.2095-3941.2024.0055","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"","journal-title":"Cancer Biol. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1130438","DOI":"10.3389\/fimmu.2023.1130438","article-title":"Advances in immune checkpoint inhibitors induced-cardiotoxicity","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-16-0194","article-title":"Assessing immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","article-title":"PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2020.08.033","article-title":"Cardiotoxic mechanisms of cancer immunotherapy - a systematic review","volume":"323","author":"Lobenwein","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3324\/haematol.2023.283818","article-title":"Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia","volume":"109","author":"Lyons","year":"2024","journal-title":"Haematologica"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12967-019-2011-3","article-title":"First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells","volume":"17","author":"Minev","year":"2019","journal-title":"J. Transl. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1002\/ehf2.13400","article-title":"Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database","volume":"8","author":"Moey","year":"2021","journal-title":"Esc. Heart Fail"},{"key":"B52","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1350585","DOI":"10.3389\/fcvm.2024.1350585","article-title":"Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach","volume":"11","author":"Murtagh","year":"2024","journal-title":"Front. Cardiovasc Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B56","doi-asserted-by":"publisher","first-page":"354","DOI":"10.21037\/atm-22-4218","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review","volume":"11","author":"Olivares-Hern\u00e1ndez","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"5","DOI":"10.20517\/jca.2024.13","article-title":"Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge","volume":"5","author":"Ostos-Mendoza","year":"2025","journal-title":"J. Cardiovasc Aging"},{"key":"B58","unstructured":"Anticytokine therapy and corticosteroids for cytokine release syndrome and for neurotoxicity following T-cell engager or CAR T-cell therapy: rapid review\n          \n          \n          2024"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur. J. Heart Fail"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.3390\/jcm14082850","article-title":"Multimodal imaging of immune checkpoint inhibitor myocarditis","volume":"14","author":"Patel","year":"2025","journal-title":"J. Clin. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/ijms25010644","article-title":"The mechanisms of altered blood-brain barrier permeability in CD19 CAR T-cell recipients","volume":"25","author":"Pinto","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians","volume":"46","author":"Raschi","year":"2023","journal-title":"Drug Saf."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e008518","DOI":"10.1136\/jitc-2023-008518","article-title":"Cardiovascular toxicities associated with bispecific T-cell engager therapy","volume":"12","author":"Sayed","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"24782","DOI":"10.1038\/s41598-025-03391-z","article-title":"Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma","volume":"15","author":"Shan","year":"","journal-title":"Sci. Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e090087","DOI":"10.1136\/bmjopen-2024-090087","article-title":"Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database","volume":"15","author":"Shan","year":"","journal-title":"BMJ Open"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e032620","DOI":"10.1161\/JAHA.123.032620","article-title":"Immune checkpoint inhibitors and cardiotoxicity: a comparative meta-analysis of observational studies and randomized controlled trials","volume":"13","author":"Sharma","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"B71","doi-asserted-by":"publisher","first-page":"113","DOI":"10.36401\/JIPO-20-10","article-title":"Cardiovascular complications of chimeric antigen receptor T-cell therapy: the cytokine release syndrome and associated arrhythmias","volume":"3","author":"Simbaqueba","year":"2020","journal-title":"J. Immunother. Precis. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.5858\/arpa.2019-0447-OA","article-title":"Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy","volume":"144","author":"Sobol","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/978-3-031-35139-6_9","article-title":"Sex-differential and non-specific effects of vaccines over the life course","volume":"441","author":"St Clair","year":"2023","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.3390\/cancers17172838","article-title":"Immunotherapy-associated cardiotoxicity: current insights and future directions for precision cardio-oncology","volume":"17","author":"Stefanou","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/heartjnl-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies","volume":"107","author":"Stein-Merlob","year":"","journal-title":"Heart"},{"key":"B76","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1002\/ehf2.13545","article-title":"Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery","volume":"8","author":"Stein-Merlob","year":"","journal-title":"Esc. Heart Fail"},{"key":"B77","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/cancers15030793","article-title":"Complete response in metastatic clear cell renal cell carcinoma patients treated with immune-checkpoint inhibitors: remission or healing? How to improve patients' outcomes?","volume":"15","author":"Thouvenin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B79","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1288172","DOI":"10.3389\/fonc.2023.1288172","article-title":"Checkpoint inhibition in hematologic malignancies","volume":"13","author":"Tsumura","year":"2023","journal-title":"Front. Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2174\/0929867324666170407125017","article-title":"Immune checkpoint inhibitors and cardiac toxicity: an emerging issue","volume":"25","author":"Varricchi","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1161\/CIRCRESAHA.121.319901","article-title":"Sex-specific cardiovascular risks of cancer and its therapies","volume":"130","author":"Wilcox","year":"2022","journal-title":"Circ. Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B86","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"B87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"Biomark. Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"33961","DOI":"10.18632\/oncotarget.5582","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00277-024-05640-z","article-title":"The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies","volume":"103","author":"Zhang","year":"2024","journal-title":"Ann. Hematol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s44272-025-00034-2","article-title":"Management of multisystemic irAEs associated with atezolizumab\/tiragolumab combination therapy in a patient with lung adenocarcinoma: case report and review","volume":"4","author":"Zhang","year":"2025","journal-title":"Clin. Cancer Bull."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1550400","DOI":"10.3389\/fimmu.2025.1550400","article-title":"ICI-induced cardiovascular toxicity: mechanisms and immune reprogramming therapeutic strategies","volume":"16","author":"Zheng","year":"2025","journal-title":"Front. Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","article-title":"CAR-T cell combination therapies in hematologic malignancies","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12967-025-06768-w","article-title":"Cardiotoxicity in cancer immunotherapy: a systematic review and global meta-analysis","volume":"23","author":"Zhou","year":"2025","journal-title":"J. Transl. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1762239\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:11:10Z","timestamp":1771924270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1762239\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":94,"alternative-id":["10.3389\/fphar.2026.1762239"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1762239","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"article-number":"1762239"}}